Keyword: Sun Pharmaceutical
The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.
Though managing director Dilip Shanghvi tried to allay investors' concerns, a couple of key questions remain unanswered.
A Chinese researcher claims is the world's first gene-edited babies; Takeda's Shire deal faces last-minute drama; Celltrion wins first Rituxan biosim nod.
Sun Pharma is picking up two manufacturing plants and a portfolio of dermatology drugs in Japan for just $1 million.
Sun Pharma will merge the operations of two plants in New Jersey and close one of them, costing dozens of workers their jobs.
Here is some news of note for the week.
Merck halves Keytruda's price in China; Takeda eyes selling Shire's Xiidra and Natpara; another ex-GSK scientist pleads guilty to trade secret theft.
India’s Sun Pharmaceuticals, which is working to shift its focus to novel and specialty drugs, has won FDA approval of a new treatment for glaucoma.
Novartis has been battling claims it illegally protected Gleevec's market, but this week the drugmaker prevailed in the cases.
FDA clears Sun Pharma's key Halol plant, Eisai builds a new drug discovery center for Alzheimer's, opposition to the Takeda-Shire deal gains support.